BACKGROUND: The management of sinonasal undifferentiated carcinoma (SNUC) remains unclear. Low incidence and poor outcomes make treatment standardization difficult. The objective of this study was to review the used treatment and our outcomes. METHODS: From 2001 to 2013, 17 cases of SNUC were treated at our department. Charts were reviewed for standard demographic, tumour size and extension, histological features, treatment strategies, surgical approach, adjuvant therapies, outcomes and complications. RESULTS: All patients presented with extensive local disease and 2 patients also had neck metastases. All patients were treated using a multimodality approach: 10 patients underwent surgery and postoperative chemoradiation, 1 patient was treated with surgery and adjuvant radiotherapy, 3 patients were treated with neoadjuvant chemotherapy, surgery and postoperative chemoradiation and the remaining 3 patients were treated with chemoradiotherapy. After median follow-up of 39 months 6 patients developed recurrences. The 3-year local control rate was 76% and the 5-year rate of overall survival was 58%. CONCLUSIONS: Management and outcomes of SNUC have improved due to advances in surgery and radiotherapy. Gross tumour resection followed by postoperative radiotherapy should be the standard of care in patients with SNUC. High-precision high-dose radiotherapy should be implemented to try to improve the outcomes.
BACKGROUND: The management of sinonasal undifferentiated carcinoma (SNUC) remains unclear. Low incidence and poor outcomes make treatment standardization difficult. The objective of this study was to review the used treatment and our outcomes. METHODS: From 2001 to 2013, 17 cases of SNUC were treated at our department. Charts were reviewed for standard demographic, tumour size and extension, histological features, treatment strategies, surgical approach, adjuvant therapies, outcomes and complications. RESULTS: All patients presented with extensive local disease and 2 patients also had neck metastases. All patients were treated using a multimodality approach: 10 patients underwent surgery and postoperative chemoradiation, 1 patient was treated with surgery and adjuvant radiotherapy, 3 patients were treated with neoadjuvant chemotherapy, surgery and postoperative chemoradiation and the remaining 3 patients were treated with chemoradiotherapy. After median follow-up of 39 months 6 patients developed recurrences. The 3-year local control rate was 76% and the 5-year rate of overall survival was 58%. CONCLUSIONS: Management and outcomes of SNUC have improved due to advances in surgery and radiotherapy. Gross tumour resection followed by postoperative radiotherapy should be the standard of care in patients with SNUC. High-precision high-dose radiotherapy should be implemented to try to improve the outcomes.
Authors: Moran Amit; Ahmed S Abdelmeguid; Teemaranawich Watcherporn; Hideaki Takahashi; Samantha Tam; Diana Bell; Renata Ferrarotto; Bonnie Glisson; Michael E Kupferman; Dianna B Roberts; Shirley Y Su; Shaan M Raza; Franco DeMonte; Ehab Y Hanna Journal: J Clin Oncol Date: 2019-01-07 Impact factor: 44.544
Authors: Francesco Perri; Raffaele Addeo; Manuel Conson; Adriana Faiella; Giuseppina Della Vittoria Scarpati; Gabriella Torre; Angela Di Biase; Paola Romanelli; Carlo Buonerba; Giuseppe Di Lorenzo; Antonio Daponte; Francesco Caponigro; Salvatore Pisconti; Roberto Pacelli; Vincenzo Ravo; Paolo Muto; Raffaele Solla Journal: Oncol Lett Date: 2017-01-11 Impact factor: 2.967
Authors: Alejandro López-Hernández; Blanca Vivanco; Alessandro Franchi; Elisabeth Bloemena; Virginia N Cabal; Sira Potes; Cristina Riobello; Cristina García-Inclán; Fernando López; José L Llorente; Mario Hermsen Journal: Sci Rep Date: 2018-03-05 Impact factor: 4.379
Authors: Muhammad Faisal; Rudolf Seemann; Claudia Lill; Sasan Hamzavi; Arno Wutzl; Boban M Erovic; Stefan Janik Journal: Head Neck Date: 2020-01-10 Impact factor: 3.147
Authors: Carolyn A Orgain; Terry Y Shibuya; Lester D Thompson; David B Keschner; Rohit Garg; Jivianne T Lee Journal: Allergy Rhinol (Providence) Date: 2017-10-01